Advent Life Sciences

Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on developing antibody modulators for immune cell receptors aimed at treating autoimmune diseases. Founded in 2018, MiroBio leverages pioneering research from the University of Oxford to understand how immune cells communicate and are activated. This foundational knowledge allows the company to create innovative antibodies that stimulate specific immune cell signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural pathways, MiroBio's therapeutics aim to provide significant benefits to patients suffering from various autoimmune conditions, enabling clinicians to effectively manage overactive immune responses associated with these diseases.

Developer of a medical discovery platform intended to connect the world's medical professionals in one place. The company's platform helps to generate new ideas, expand the network, and discover medical events, as well as assists in job search, enabling professional teams to share their work in a hassle-free way and stay informed.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Founded in 2013 and based in Cambridge, Massachusetts, the company specializes in small-molecule drugs that act as immunomodulators. Its lead compound, AX-024, specifically targets Nck, disrupting the interaction that activates T-cells, thereby preventing harmful responses against antigens while maintaining the immune system's ability to combat infections. Artax Biopharma's research encompasses a range of conditions, including asthma, rheumatoid arthritis, psoriasis, graft versus host disease, and multiple sclerosis. By aiming to treat both symptoms and underlying disease mechanisms, the company's therapies are designed to minimize side effects associated with traditional treatments.

Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, and bioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal.

Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.

AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, established in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on treatments for conditions related to intense pruritus, particularly in patients undergoing targeted anti-cancer therapies. Its lead asset, orvepitant, is an oral NK-1 antagonist designed to alleviate this specific symptom. Additionally, NeRRe is advancing other candidates, including NT-814, a dual NK-1 and NK-3 antagonist, and NT-949, which is ready for Phase I trials. The company also has NT-432, a clinical candidate targeting NK-1 receptors. NeRRe Therapeutics aims to address unmet medical needs through its innovative therapeutic approaches.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

Wiz, Inc. is a cloud security company that designs and develops a comprehensive platform to help enterprises secure their cloud infrastructure. Founded in 2020 and headquartered in Palo Alto, California, with an additional office in Tel Aviv, Israel, Wiz provides organizations with real-time visibility into their cloud environments. The platform enables businesses to assess risks, identify vulnerabilities, manage identities and privileges, and detect misconfigurations across various cloud services, containers, and workloads. By offering insights without the need for agents or sidecars, Wiz empowers enterprises to effectively manage their security posture and protect sensitive information.

Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, founded in 2017. The company specializes in targeted protein degradation technology, which is aimed at developing innovative cancer therapeutics. Amphista's approach leverages the body's natural processes to selectively degrade and eliminate proteins that contribute to disease progression. By advancing next-generation therapeutics, the company seeks to improve treatment efficacy and enhance patient outcomes across a range of diseases. Amphista's research focuses on identifying novel methods to modulate the cell's degradation machinery, thereby addressing the underlying mechanisms of various conditions.

Bioncotech is a development stage bio-pharma company focused on the development of a new concept of anticancer therapy for the treatment of tumors such as metastatic melanoma, glioblastoma, bladder, or pancreatic cancer. The company is a spin-off of the Spanish National Cancer Research Centre, one of the leading international centers in cancer research. It Therapeutics is a biopharmaceutical company dedicated to the development of new oncologic treatments. The company develops and manages projects throughout the value-creation chain: from formulation, manufacturing, and preclinical development to clinical trials with the support of other institutions and pharmaceutical companies. Founded in 2012 by [Maria Gonzalez](https://www.crunchbase.com/person/maria-gonzalez-2), Bioncotech is headquartered in Paterna with other designations in Madrid, Spain and Cambridge, Massachusetts.

Rappta Therapeutics Oy is a biopharmaceutical company focused on developing innovative anti-cancer drugs that target protein phosphatase 2A (PP2A), a vital enzyme involved in regulating protein de-phosphorylation and tumor growth. Established in 2019 and headquartered in Helsinki, Finland, with an additional office in the United States, the company is in the lead-optimization stage of creating a first-in-class series of molecules aimed at reactivating this key tumor suppressor. The firm employs proprietary development tools to facilitate rational drug design, aiming to provide therapeutic solutions for various cancer types and select non-oncology conditions.

F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.

Zikani Therapeutics, Inc. develops and commercializes therapeutics for patients with limited treatment options. It offers TURBO-ZM, a platform to develop novel ribosome modulating agents (RMAs) for the treatment of cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Zikani Therapeutics, Inc. was formerly known as Macrolide Pharmaceuticals, Inc. and changed its name to Zikani Therapeutics, Inc. in February 2015. Zikani Therapeutics, Inc. was incorporated in 2014 and is based in Watertown, Massachusetts.

PIC Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative cancer treatments through the selective modulation of oncogene translation. Founded in 2016, the company aims to improve patient outcomes by targeting key components of cancer signaling pathways. Its therapeutics work by modulating the pre-initiation complex that facilitates messenger RNA translation, effectively blocking the production of oncogene proteins. This precision-based approach has the potential to address multiple oncogenic drivers simultaneously, paving the way for a new generation of effective cancer therapies.

Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, founded in 2017. The company specializes in targeted protein degradation technology, which is aimed at developing innovative cancer therapeutics. Amphista's approach leverages the body's natural processes to selectively degrade and eliminate proteins that contribute to disease progression. By advancing next-generation therapeutics, the company seeks to improve treatment efficacy and enhance patient outcomes across a range of diseases. Amphista's research focuses on identifying novel methods to modulate the cell's degradation machinery, thereby addressing the underlying mechanisms of various conditions.

AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on developing antibody modulators for immune cell receptors aimed at treating autoimmune diseases. Founded in 2018, MiroBio leverages pioneering research from the University of Oxford to understand how immune cells communicate and are activated. This foundational knowledge allows the company to create innovative antibodies that stimulate specific immune cell signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural pathways, MiroBio's therapeutics aim to provide significant benefits to patients suffering from various autoimmune conditions, enabling clinicians to effectively manage overactive immune responses associated with these diseases.

Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at treating autoimmune diseases and inflammatory disorders. The company specializes in a unique peptide that helps maintain a cluster of truncated CD31 molecules at the cell membrane, which allows for the modulation of overactive immune responses without complete blockade. By providing this innovative approach, Tridek-One enables medical companies to offer improved treatment options for patients, enhancing their quality of life.

KANDY THERAPEUTICS LIMITED develops non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening. The company offers NT-814, a drug for common, chronic debilitating female sex-hormone related treatment. It provides non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment, and reduce symptoms of hormone related conditions. The company was founded in 2017 and is based in Stevenage, United Kingdom. KANDY THERAPEUTICS LIMITED operates as a subsidiary of Bayer Aktiengesellschaft.

Zikani Therapeutics, Inc. develops and commercializes therapeutics for patients with limited treatment options. It offers TURBO-ZM, a platform to develop novel ribosome modulating agents (RMAs) for the treatment of cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Zikani Therapeutics, Inc. was formerly known as Macrolide Pharmaceuticals, Inc. and changed its name to Zikani Therapeutics, Inc. in February 2015. Zikani Therapeutics, Inc. was incorporated in 2014 and is based in Watertown, Massachusetts.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

Vestagen Technical Textiles is a company based in Orlando, Florida, that develops, manufactures, and markets high-performance textile products for the healthcare sector and beyond. Founded in 2009, it offers a range of items including lab coats and uniforms specifically designed for specialty healthcare workers and patients. The company holds exclusive North American rights to patented Swiss technologies that enable the adaptation of its textiles for various applications, including medical uniforms and athletic apparel. Vestagen sells its products directly to consumers and through retail partners, distributors, and online platforms, ensuring broad accessibility to its innovative textile solutions.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company based in Dublin, Ireland, focused on developing innovative anti-infectives to address the global challenge of multi-drug resistant pathogens. Founded in 2015, the company is advancing sulopenem, a novel penem anti-infective compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem aims to treat uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. The company's goal is to provide effective solutions for serious infections caused by resistant bacteria, thereby improving patient outcomes and addressing the limitations of existing antibiotic treatments.

Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, established in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on treatments for conditions related to intense pruritus, particularly in patients undergoing targeted anti-cancer therapies. Its lead asset, orvepitant, is an oral NK-1 antagonist designed to alleviate this specific symptom. Additionally, NeRRe is advancing other candidates, including NT-814, a dual NK-1 and NK-3 antagonist, and NT-949, which is ready for Phase I trials. The company also has NT-432, a clinical candidate targeting NK-1 receptors. NeRRe Therapeutics aims to address unmet medical needs through its innovative therapeutic approaches.

Aleta Biotherapeutics, founded in 2015 and based in Natick, Massachusetts, specializes in the development of immuno-oncology drugs aimed at addressing intractable cancerous tumors. The company focuses on transforming cellular therapeutics to target a wider range of cancer indications, including currently challenging solid tumors. By enabling healthcare professionals to effectively and efficiently treat patients, Aleta Biotherapeutics is positioned to contribute significantly to advancements in cancer treatment.

F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.

Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.

Capella Bioscience Limited is involved in the discovery and development of monoclonal antibodies (mAbs) for therapeutic applications. The company utilizes proprietary technologies to create and commercialize mAb-based medicines targeting oncology, autoimmune diseases, and other conditions. Founded in 2014 and headquartered in London, the firm operates both independently and in collaboration with biotechnology firms and academic institutions to advance its research and development efforts. Through its innovative approach, Capella Bioscience aims to contribute to the development of advanced medical therapies that address significant health challenges.

Vestagen Technical Textiles is a company based in Orlando, Florida, that develops, manufactures, and markets high-performance textile products for the healthcare sector and beyond. Founded in 2009, it offers a range of items including lab coats and uniforms specifically designed for specialty healthcare workers and patients. The company holds exclusive North American rights to patented Swiss technologies that enable the adaptation of its textiles for various applications, including medical uniforms and athletic apparel. Vestagen sells its products directly to consumers and through retail partners, distributors, and online platforms, ensuring broad accessibility to its innovative textile solutions.

Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Founded in 2013 and based in Cambridge, Massachusetts, the company specializes in small-molecule drugs that act as immunomodulators. Its lead compound, AX-024, specifically targets Nck, disrupting the interaction that activates T-cells, thereby preventing harmful responses against antigens while maintaining the immune system's ability to combat infections. Artax Biopharma's research encompasses a range of conditions, including asthma, rheumatoid arthritis, psoriasis, graft versus host disease, and multiple sclerosis. By aiming to treat both symptoms and underlying disease mechanisms, the company's therapies are designed to minimize side effects associated with traditional treatments.

Vestagen Technical Textiles is a company based in Orlando, Florida, that develops, manufactures, and markets high-performance textile products for the healthcare sector and beyond. Founded in 2009, it offers a range of items including lab coats and uniforms specifically designed for specialty healthcare workers and patients. The company holds exclusive North American rights to patented Swiss technologies that enable the adaptation of its textiles for various applications, including medical uniforms and athletic apparel. Vestagen sells its products directly to consumers and through retail partners, distributors, and online platforms, ensuring broad accessibility to its innovative textile solutions.

Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

WorldStores Limited is the largest online retailer of home and garden products in the United Kingdom. Established in 2008 and based in Twickenham, the company specializes in a diverse range of offerings, including bedroom furniture, living room and dining room furnishings, homewares, outdoor products, and DIY items. Their product selection encompasses everything from beds and mattresses to garden furniture, appliances, and decorative items like wallpapers and lighting. WorldStores also caters to families with a variety of children's products, including nursery items and outdoor play equipment. The company is part of the Worldstores Group, which includes ACHICA, a luxury flash-sale site, and Kiddicare, a baby specialist, both of which contribute to WorldStores' ambition to become a leading name in the home and garden sector. WorldStores is recognized for its extensive choice, competitive pricing, customer service, and flexible delivery options.

gmp-orphan (GMPO), it is their mission to identify, develop and provide access to innovative treatments to patients with rare diseases. Their experienced pharmaceutical development and commercial team in the field of rare diseases is critical in advancing this mission.

Calcico Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, focused on developing novel small molecule drugs for autoimmune and inflammatory disorders. Founded in 2012, the company specializes in creating selective inhibitors of calcium-release activated channels (CRAC), targeting conditions with established links to CRAC dysfunction. Calcico has developed proprietary systems for CRAC channel screening and molecule characterization, placing it in a unique position to achieve effective and selective CRAC channel inhibition, a challenge that has been difficult for larger pharmaceutical companies to address. Through its innovative approach, Calcico aims to provide new treatment options for various inflammatory and autoimmune diseases, including atopic dermatitis.

Levicept Ltd. is a biotechnology company based in Sandwich, United Kingdom, founded in 2012. The company focuses on developing innovative biological therapies for chronic pain management, specifically targeting conditions such as osteoarthritis and neuropathic pain. Levicept is advancing a novel therapy, LEVI-04 (p75NTR-Fc), which aims to restore neurotrophin homeostasis by stabilizing binding proteins for excess neurotrophins associated with chronic pain states. This approach seeks to address the significant unmet medical need for safe and effective analgesics, particularly given the limitations and adverse effects of traditional non-steroidal anti-inflammatory drugs (NSAIDs). Levicept is currently progressing LEVI-04 into phase I clinical trials to evaluate its safety and efficacy in patients with osteoarthritis.

Farfetch operates an online luxury fashion retail platform that connects various independent boutiques worldwide. Founded in 2008 by Jose Neves and headquartered in London, the company offers a wide range of products, including bags, coats, dresses, jackets, jewelry, swimwear, trousers, shoes, knitwear, suits, shorts, and accessories for women, men, and children. Farfetch's modular technology platform is designed to meet the complex needs of consumers and luxury sellers, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. Additionally, Farfetch has a dedicated division, Farfetch China, which focuses on enhancing connections within the luxury fashion industry in that market.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Vestagen Technical Textiles is a company based in Orlando, Florida, that develops, manufactures, and markets high-performance textile products for the healthcare sector and beyond. Founded in 2009, it offers a range of items including lab coats and uniforms specifically designed for specialty healthcare workers and patients. The company holds exclusive North American rights to patented Swiss technologies that enable the adaptation of its textiles for various applications, including medical uniforms and athletic apparel. Vestagen sells its products directly to consumers and through retail partners, distributors, and online platforms, ensuring broad accessibility to its innovative textile solutions.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Vestagen Technical Textiles is a company based in Orlando, Florida, that develops, manufactures, and markets high-performance textile products for the healthcare sector and beyond. Founded in 2009, it offers a range of items including lab coats and uniforms specifically designed for specialty healthcare workers and patients. The company holds exclusive North American rights to patented Swiss technologies that enable the adaptation of its textiles for various applications, including medical uniforms and athletic apparel. Vestagen sells its products directly to consumers and through retail partners, distributors, and online platforms, ensuring broad accessibility to its innovative textile solutions.

Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

WorldStores Limited is the largest online retailer of home and garden products in the United Kingdom. Established in 2008 and based in Twickenham, the company specializes in a diverse range of offerings, including bedroom furniture, living room and dining room furnishings, homewares, outdoor products, and DIY items. Their product selection encompasses everything from beds and mattresses to garden furniture, appliances, and decorative items like wallpapers and lighting. WorldStores also caters to families with a variety of children's products, including nursery items and outdoor play equipment. The company is part of the Worldstores Group, which includes ACHICA, a luxury flash-sale site, and Kiddicare, a baby specialist, both of which contribute to WorldStores' ambition to become a leading name in the home and garden sector. WorldStores is recognized for its extensive choice, competitive pricing, customer service, and flexible delivery options.

Farfetch operates an online luxury fashion retail platform that connects various independent boutiques worldwide. Founded in 2008 by Jose Neves and headquartered in London, the company offers a wide range of products, including bags, coats, dresses, jackets, jewelry, swimwear, trousers, shoes, knitwear, suits, shorts, and accessories for women, men, and children. Farfetch's modular technology platform is designed to meet the complex needs of consumers and luxury sellers, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. Additionally, Farfetch has a dedicated division, Farfetch China, which focuses on enhancing connections within the luxury fashion industry in that market.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Avidex is an award-winning, full service audiovisual firm. An innovative leader in the design, integration, project management, equipment procurement and support services of audiovisual solutions for commercial and healthcare clients throughout the U.S. Avidex also offers a broad range of equipment rental and show services. Avidex successfully partners with architects, contractors, consultants, educators and executives to create boardrooms, videoconference rooms, auditoriums, training facilities, digital signage and many additional projects that incorporate audiovisual needs. With a current staff of over 130 employees, the people at Avidex have the background and knowledge to provide you with the best possible experience in implementing audiovisual and multimedia technologies. Over the past 10 years Avidex has successfully completed many International jobs in more than a dozen different countries ranging from Europe to Asia and has completed jobs in over 26 states. Avidex is a true single source for all audiovisual needs.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, established in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on treatments for conditions related to intense pruritus, particularly in patients undergoing targeted anti-cancer therapies. Its lead asset, orvepitant, is an oral NK-1 antagonist designed to alleviate this specific symptom. Additionally, NeRRe is advancing other candidates, including NT-814, a dual NK-1 and NK-3 antagonist, and NT-949, which is ready for Phase I trials. The company also has NT-432, a clinical candidate targeting NK-1 receptors. NeRRe Therapeutics aims to address unmet medical needs through its innovative therapeutic approaches.

CardiAQ Valve Technologies (CVT), a privately held company, is developing innovative approaches to heart valve replacement and is initially focused on transcatheter mitral valve implantation (TMVI).

F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.

Ubiquisys is a mobile communications company specializing in the design and development of devices for mobile operators and consumers. The company is recognized for its ZoneGate femtocell system, a compact plug-and-play device that connects to home or office broadband, delivering 3G coverage and supporting various mobile services. Ubiquisys is also a leader in intelligent small cell technology, with its products deployed by over 70 operators worldwide. Additionally, the company offers solutions in the wireless-wireline convergence market, enhancing connectivity in both residential and commercial settings.

CN Creative, headquartered in the Bioscience Incubator at Manchester University in the UK, focuses on addressing global challenges linked to smoking and smoking-related illnesses through innovative and sustainable solutions. The company has developed a range of products and services aimed at smoking cessation and harm reduction. Its offerings include QuitDirect, an NHS-accredited provider of smoking cessation services, the Intellicig® electronic cigarette, and ECOpure, a line of proprietary high-purity nicotine preparations. Additionally, CN Creative offers NRT Direct, which supplies traditional nicotine replacement therapy products and support services for both public and private smoking cessation programs. Currently, the Nicadex(TM) electronic inhaler, a nicotine replacement therapy product, is in clinical development for use in medically supervised smoking cessation initiatives.

Farfetch operates an online luxury fashion retail platform that connects various independent boutiques worldwide. Founded in 2008 by Jose Neves and headquartered in London, the company offers a wide range of products, including bags, coats, dresses, jackets, jewelry, swimwear, trousers, shoes, knitwear, suits, shorts, and accessories for women, men, and children. Farfetch's modular technology platform is designed to meet the complex needs of consumers and luxury sellers, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. Additionally, Farfetch has a dedicated division, Farfetch China, which focuses on enhancing connections within the luxury fashion industry in that market.

Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.

WorldStores Limited is the largest online retailer of home and garden products in the United Kingdom. Established in 2008 and based in Twickenham, the company specializes in a diverse range of offerings, including bedroom furniture, living room and dining room furnishings, homewares, outdoor products, and DIY items. Their product selection encompasses everything from beds and mattresses to garden furniture, appliances, and decorative items like wallpapers and lighting. WorldStores also caters to families with a variety of children's products, including nursery items and outdoor play equipment. The company is part of the Worldstores Group, which includes ACHICA, a luxury flash-sale site, and Kiddicare, a baby specialist, both of which contribute to WorldStores' ambition to become a leading name in the home and garden sector. WorldStores is recognized for its extensive choice, competitive pricing, customer service, and flexible delivery options.

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease. Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.

Ampla Pharmaceuticals designs and develops biopharmaceutical drugs. The company was incorporated in 2006 and is based in La Jolla, California.

Vitrue offers the industry’s most scalable and secure cloud-based social marketing solution, enabling brands to harness the full marketing potential of social on Facebook, Twitter, Google+, YouTube and emerging platforms. The award-winning Vitrue SRM platform collectively manages more than one billion social relationships in over 100 countries across more than 4,500 social accounts for its clients. For more information, visit www.vitrue.com.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative therapeutics for liver diseases and chronic conditions with significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company has focused on its lead product candidate, Emricasan, an orally active caspase protease inhibitor currently in Phase IIb clinical trials for various liver-related conditions, including post-orthotopic liver transplant complications and liver fibrosis linked to nonalcoholic steatohepatitis. Additionally, Conatus is advancing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage for treating chronic diseases associated with inflammasome pathways. The company has also entered into a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.

They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition. The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.

Pathwork Diagnostics, located in Redwood City, California, specializes in molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This innovative test assists in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. The test leverages genomic information from a tumor to enhance diagnostic precision and can be applied to various specimen types, including frozen tissue and formalin-fixed, paraffin-embedded samples. Through its advanced diagnostic solutions, Pathwork Diagnostics aims to improve clinical outcomes in cancer care.

Ubiquisys is a mobile communications company specializing in the design and development of devices for mobile operators and consumers. The company is recognized for its ZoneGate femtocell system, a compact plug-and-play device that connects to home or office broadband, delivering 3G coverage and supporting various mobile services. Ubiquisys is also a leader in intelligent small cell technology, with its products deployed by over 70 operators worldwide. Additionally, the company offers solutions in the wireless-wireline convergence market, enhancing connectivity in both residential and commercial settings.

AmberFin enables content owners to maximize the value of their TV, film and video content, from capture through to distribution, while increasing revenues, reducing costs, saving time and eliminating incompatibility issues. AmberFin iCR, with four-time Emmy-award winning technology, plays a key role in turning the content that owners have into the content their customers want. As an open standards, future proof platform that digitizes and transforms new and archived content, AmberFin iCR delivers the best quality pictures at smaller file sizes across multiple delivery platforms, including the Internet, VoD, TV, mobile and other small screen devices.

OpenCloud, formed in 2000 is a privately funded company. It provides the telecommunications industry with a real-time Application Server for agile development, deployment and efficient management of person-to-person communications services across current and next generation network technology.

Ubiquisys is a mobile communications company specializing in the design and development of devices for mobile operators and consumers. The company is recognized for its ZoneGate femtocell system, a compact plug-and-play device that connects to home or office broadband, delivering 3G coverage and supporting various mobile services. Ubiquisys is also a leader in intelligent small cell technology, with its products deployed by over 70 operators worldwide. Additionally, the company offers solutions in the wireless-wireline convergence market, enhancing connectivity in both residential and commercial settings.

Farfetch operates an online luxury fashion retail platform that connects various independent boutiques worldwide. Founded in 2008 by Jose Neves and headquartered in London, the company offers a wide range of products, including bags, coats, dresses, jackets, jewelry, swimwear, trousers, shoes, knitwear, suits, shorts, and accessories for women, men, and children. Farfetch's modular technology platform is designed to meet the complex needs of consumers and luxury sellers, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. Additionally, Farfetch has a dedicated division, Farfetch China, which focuses on enhancing connections within the luxury fashion industry in that market.

Avila Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in the design and development of covalent drugs targeting viral infections, cancers, and autoimmune diseases. One of its key products is AVL-181, a small molecule designed to inhibit the protease of the hepatitis C virus. Founded in 2006, Avila Therapeutics has entered into a strategic alliance with Sanofi-Aventis and, as of 2012, operates as a subsidiary of Celgene Corporation. The company's innovative approach focuses on creating therapies that can provide significant benefits in the treatment of challenging medical conditions.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.

Oxagen Limited, a biopharmaceutical company, develops and commercializes anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. Its drug programs target the CRTH2 receptor that initiates and maintains allergic conditions. The company develops a pipeline of small molecule drugs. It serves customers in the United Kingdom, Russia, CIS countries, and internationally. Oxagen Limited was incorporated in 1996 and is based in London, United Kingdom.

Dailymotion is a prominent independent video-sharing platform launched in 2005, designed for users to discover diverse content across various categories including news, sports, music, and entertainment. With a global audience of approximately 300 million users, Dailymotion focuses on delivering premium content from reputable publishers while also providing a space for user-generated uploads, averaging 600,000 per month. The platform features over 30,000 channels, allowing content creators to share their videos and monetize their work through contextual advertising. Dailymotion partners with major content providers such as Universal Music Group, BBC News, and VICE, enhancing the quality and variety of its offerings. Owned by Vivendi, Dailymotion aims to connect video makers with audiences and facilitate an engaging viewing experience.

The Fizzback Group, founded in 2004, specializes in customer engagement solutions that empower companies to effectively capture and respond to customer feedback in real-time. Utilizing a unique artificial intelligence engine, the Fizzback platform analyzes feedback at the point of experience, allowing businesses to generate relevant responses and take informed actions based on insights derived from customer comments. This innovative approach helps companies understand the voice of their customers, particularly those who may have previously remained silent. By enhancing customer engagement, Fizzback enables organizations to increase customer lifetime value and foster positive word-of-mouth, ultimately driving economic benefits.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.

Foundry is a company with a 20-year history that specializes in computer graphics, visual effects, and 3D design software. The company develops award-winning products that enhance visual experiences and is dedicated to collaborating with creative professionals worldwide. Foundry's software is widely utilized in the production of visual effects for feature films, video-on-demand content, television shows, and commercials, enabling artists and designers to create stunning visual sequences. Through its innovative technology, Foundry continues to play a significant role in the design and visual industries.

BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Qype is a social network focused on user-generated reviews of businesses and locations. Established in 2005 by German entrepreneur Stephan Uhrenbacher, the platform allows users to explore a comprehensive database of businesses, highlighting those that have received positive ratings from the community. Members can contribute by adding new locations, rating and reviewing existing entries, and sharing multimedia content such as videos and photos. Additionally, Qype fosters community engagement through message boards and groups. The site also features a mobile version, enabling users to find top-rated businesses near their current location.

OpenCloud, formed in 2000 is a privately funded company. It provides the telecommunications industry with a real-time Application Server for agile development, deployment and efficient management of person-to-person communications services across current and next generation network technology.

EUSA Pharma, established in March 2015 and headquartered in the UK, is a specialty pharmaceutical company with a global presence, particularly in Europe and the USA. The company specializes in oncology and critical diseases, offering a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®. EUSA Pharma focuses on addressing rare diseases and conditions like oral mucositis, a debilitating side effect of cancer treatments, with effective biopharmaceutical solutions. The firm submitted a marketing authorization application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma in early 2016. EUSA Pharma aims to expand its product offerings through acquisitions and in-licensing, supported by significant funding from prominent life science investors. With direct commercial operations and a distribution network that spans approximately 40 countries, EUSA Pharma is well-positioned to meet the needs of patients worldwide.

Orecon Ltd. is a company based in Bodmin, United Kingdom, that specializes in the development of wave energy devices. Founded in 2002, Orecon focuses on harnessing the immense power of the oceans to generate sustainable and affordable electricity. The company offers innovative solutions, including oscillating water column technology and multi resonant chambers for wave energy conversion. Orecon's multi resonant chamber (MRC) is designed to be robust and reliable, utilizing high-quality, proven components. Committed to environmental stewardship, Orecon prioritizes the protection of ocean ecosystems while striving to convert wave energy into renewable power.

Wisair is a fabless semiconductor company providing single-chip based Ultra Wideband (UWB) and Wireless USB solutions for personal computing, consumer electronics, and mobile devices.

Moveme.com is an online marketplace based in the U.K. that offers free, instant quotes for various moving-related services. The platform connects users with local moving-service providers, allowing them to easily compare options for moving and removal services. In addition to moving solutions, Moveme.com also facilitates access to home insurance, tradespeople, mortgage services, as well as television and broadband providers, and energy performance certificates. This comprehensive approach aims to streamline the moving process by providing essential services in one convenient web portal.

They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition. The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.

Audium Semiconductor is a fabless semiconductor company based in Bristol, U.K., specializing in the development of innovative and efficient audio power amplifier products for the consumer electronics market. Founded in March 2006 by Clyde Witchard and Huw Davies, Audium focuses on creating advanced audio amplifier and integrated circuit devices. The company's commitment to innovation positions it as a key player in the audio technology sector, catering to the growing demands of consumer electronics.

Dailymotion is a prominent independent video-sharing platform launched in 2005, designed for users to discover diverse content across various categories including news, sports, music, and entertainment. With a global audience of approximately 300 million users, Dailymotion focuses on delivering premium content from reputable publishers while also providing a space for user-generated uploads, averaging 600,000 per month. The platform features over 30,000 channels, allowing content creators to share their videos and monetize their work through contextual advertising. Dailymotion partners with major content providers such as Universal Music Group, BBC News, and VICE, enhancing the quality and variety of its offerings. Owned by Vivendi, Dailymotion aims to connect video makers with audiences and facilitate an engaging viewing experience.

BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Avila Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in the design and development of covalent drugs targeting viral infections, cancers, and autoimmune diseases. One of its key products is AVL-181, a small molecule designed to inhibit the protease of the hepatitis C virus. Founded in 2006, Avila Therapeutics has entered into a strategic alliance with Sanofi-Aventis and, as of 2012, operates as a subsidiary of Celgene Corporation. The company's innovative approach focuses on creating therapies that can provide significant benefits in the treatment of challenging medical conditions.

Ubiquisys is a mobile communications company specializing in the design and development of devices for mobile operators and consumers. The company is recognized for its ZoneGate femtocell system, a compact plug-and-play device that connects to home or office broadband, delivering 3G coverage and supporting various mobile services. Ubiquisys is also a leader in intelligent small cell technology, with its products deployed by over 70 operators worldwide. Additionally, the company offers solutions in the wireless-wireline convergence market, enhancing connectivity in both residential and commercial settings.

Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative therapeutics for liver diseases and chronic conditions with significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company has focused on its lead product candidate, Emricasan, an orally active caspase protease inhibitor currently in Phase IIb clinical trials for various liver-related conditions, including post-orthotopic liver transplant complications and liver fibrosis linked to nonalcoholic steatohepatitis. Additionally, Conatus is advancing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage for treating chronic diseases associated with inflammasome pathways. The company has also entered into a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.

The Fizzback Group, founded in 2004, specializes in customer engagement solutions that empower companies to effectively capture and respond to customer feedback in real-time. Utilizing a unique artificial intelligence engine, the Fizzback platform analyzes feedback at the point of experience, allowing businesses to generate relevant responses and take informed actions based on insights derived from customer comments. This innovative approach helps companies understand the voice of their customers, particularly those who may have previously remained silent. By enhancing customer engagement, Fizzback enables organizations to increase customer lifetime value and foster positive word-of-mouth, ultimately driving economic benefits.

Echovox SA is a company that specializes in mobile monetization solutions, facilitating the monetization of web, media, and mobile content through mobile transactions. Established in 2000 and headquartered in Carouge, Switzerland, Echovox operates a unique gateway infrastructure that supports premium SMS, Bulk, and WAP billing across more than 20 countries, connecting over 100 mobile carriers and covering more than 500 million subscribers. The company develops and distributes a variety of applications, including entertainment, chat, games, quizzes, and news. Additionally, Echovox creates and manages mobile advertising and marketing campaigns, as well as offers tools for voting, call TV, and text-to-screen applications that enhance audience interaction with television programs. With extensive experience in the mobile payment industry, Echovox provides comprehensive solutions to media companies, mobile content providers, and application developers, enabling them to effectively monetize their traffic while also offering services such as two-factor authentication.

4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.

OpenCloud, formed in 2000 is a privately funded company. It provides the telecommunications industry with a real-time Application Server for agile development, deployment and efficient management of person-to-person communications services across current and next generation network technology.